Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233753 | 0.93 | TSHR (0.58) | TSHRALDH1A1TRPA1PDE4ACYP11B2 | |
| SCHEMBL16298420 | 0.80 | TSHR (0.50) | TSHRALDH1A1PDE4ACYP11B2PDE4B | |
| SCHEMBL715508 | 0.74 | ALDH1A1 (0.52) | TSHRALDH1A1PDE4ACYP11B2PDE4B | |
| SCHEMBL235836 | 0.74 | ALDH1A1 (0.54) | TSHRALDH1A1PDE4ACYP11B2PDE5A | |
| SCHEMBL237742 | 0.74 | PDE5A (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7440439 | 0.74 | PDE5A (0.67) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL193091 | 0.74 | PDE5A (0.67) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL237741 | 0.74 | PDE5A (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL193092 | 0.74 | PDE5A (0.67) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL237740 | 0.74 | PDE5A (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | claimed |
| US-20100323997-A1 | NOVEL USES | INTRACELLULAR THERAPIES, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | claimed |
| EP-2081431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | claimed |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180280396-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2010098839-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2081431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5393755-A | Hypotensive agents, enzyme inhibitors | SCHERING CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | TSHR 3127/4885ALDH1A1 22/4885MEN1 4007/4885 |
| US-20180280396-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | TSHR 3127/4885ALDH1A1 22/4885MEN1 4007/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | TSHR 3845/4885ALDH1A1 1254/4885MEN1 3234/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | TSHR 4085/4885ALDH1A1 79/4885MEN1 2893/4885 |
| US-20100323997-A1 | NOVEL USES | PDE5A, PDE2A, PDE3A | TSHR 810/4885ALDH1A1 483/4885MEN1 4471/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | TSHR 3127/4885ALDH1A1 22/4885MEN1 4007/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | TSHR 3757/4885ALDH1A1 1873/4885MEN1 3784/4885 |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | PDE12, PDE5A, PDE3A | TSHR 3924/4885ALDH1A1 397/4885MEN1 2024/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | TSHR 3893/4885ALDH1A1 1336/4885MEN1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.